Gefitinib is a quinazoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It inhibits the autophosphorylation of tyrosine kinase domain in EGFR cells by competitive binding to ATP and blocks the transmission of downstream signals, so as to inhibit tumor angiogenesis, cell proliferation, invasion and metastasis and promote apoptosis.